None listed
Conditions
Interventions
Intravenous labetolol with oral placebo being tablet Vitamin C
Oral Nifedipine and also sterile water will serve as a placebo
Sponsors
MBEREOBONG SATURDAY ETUK
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Pregnant women that are 18years and above. 2. Pregnant women that are 28weeks and above. 3. Pregnant women with severe hypertension (systolic blood pressure =160 mm Hg or diastolic blood pressure =110 mm Hg) and are able to swallow oral medications. 4. Eligible pregnant women who give their informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant women with a history of cardiac disease. 2. Pregnant women with bronchial asthma. 3. Pregnant women with a haematological disorder. 4. Pregnant women with a history of allergy to labetalol or nifedipine. 5. Pregnant women with a history of diabetes mellitus. 6. Pregnant women with a history of liver disorder. 7. Pregnant women with a history of chronic hypertension. 8. Pregnant women who have taken antihypertensive treatment in the preceding 72hrs. 9. Pulse rate 120 beats/ minute.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is to compare the efficacy of intravenous labetalol with that of oral nifedipine in the control of blood pressure in women with severe hypertensive disorders in pregnancy. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome measures would be to determine the prevalence of hypertensive disorders of pregnancy in the UUTH, as well as the time and number of doses of intravenous labetalol and oral nifedipine necessary to achieve target blood pressure of 150/100mmHg. It also includes the adverse effects experienced with both medications. | — |
Countries
Nigeria
Contacts
Public ContactOku Okoiseh
Senior Registrar
Outcome results
None listed